Litigation Details for Acuitas Therapeutics Inc. v. Genevant Sciences GmbH (S.D.N.Y. 2022)

✉ Email this page to a colleague

The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2022-03-18	1	Complaint	Therapeutics Inc.. (Attachments: # 1 Exhibit A-US 8,058,069, # 2 Exhibit B-US 8,492,359, # 3 Exhibit C-US …2022 7 August 2023 1:22-cv-02229 830 Patent None District Court, S.D. New York	External link to document
2022-09-06	42	Amended Complaint	Exhibit A-US Patent No. 8,058,069, # 3 Exhibit B-US Patent No. 8,492,359, # 4 Exhibit C-US Patent No. 8,822,668…Exhibit D-US Patent No. 9,006,417, # 6 Exhibit E-US Patent No. 9,364,435, # 7 Exhibit F-US Patent No. 9,404,127…Exhibit G-US Patent No. 9,504,651, # 9 Exhibit H-US Patent No. 9,518,272, # 10 Exhibit I-US Patent No. 11,141,378…2022 7 August 2023 1:22-cv-02229 830 Patent None District Court, S.D. New York	External link to document
2022-10-04	44	Memorandum of Law in Support of Motion	See, e.g., Dkt. 1-1 (U.S. Patent No. 8,058,069, claim 1). All the patents require both a nucleic acid…for two patents, the ’502 patent and the ’402 patent mentioned above. Addressing each patent in turn,…multiple patents. A product infringing the patentee’s patent might therefore also apply the patents of third…claim of nine patents owned by Arbutus and licensed to Genevant (“Defendants’ Patents”) and that Defendants…2018, BNT licensed Defendants’ Patents from Genevant, among other patents, in connection with BNT’s development	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document